home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410p.zip
/
M94A3132.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
38 lines
Document 3132
DOCN M94A3132
TI The prevalence of slow progressors in HIV-1 infection in Galicia, Spain.
DT 9412
AU Castro A; Hermida M; Pereiro C; Lopez Calvo MS; Ruanova S; Moreno J;
Pedreira J; Internal Medicine Service, Hospital Juan Canolejo, La
Coruna.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):146 (abstract no. PB0011). Unique
Identifier : AIDSLINE ICA10/94369443
AB ++OBJECTIVES: To analyse the prevalence of patients with slow progressor
criteria (SP) (patients infected > 5 years and CD4 counts > 500/mm3 with
no antirretrovirical treatment) in HIV-1 in the La Coruna area of
500,000 inhabitants (Galicia, Northwestern Spain). METHODS: 804 HIV-1
positive patients were studied between 1984 and 1994 in our hospital;
581 men and 223 women with a mean age of 26.9 + 0.25 years. Risk factors
were: 80.7% intravenous drug abusers, 5.8% heterosexual transmission,
2.7% homo/bisexual, 0.8% post-transfussional, 10% others. Average study
period 2.96 years (range: 30 days-10.07 years) 302 were AIDS cases.
RESULTS: The global prevalence of SP patients was 17/804 (2.1%); 17/133
(12.7%) in those followed for > 5 years. 12 were men and 5 women, with a
mean age of 24.3 + 1.29 years. All of them were intravenous druf
abusers, followed for 5.48 years (range: 5.08 + 10.07); mean CD4 cell
count was initially 1146 + 124/mm3 and finally 1009 + 92/mm3. There were
no epidemiological difference with non slow progressors patients.
CONCLUSIONS: 1. The prevalence of slow progressors HIV-1 patients is low
in Galicia. 2. All slow progressors patients were intravenous drug
abusers. 3. CD4 cell counts remained stable in all slow progressors
patients during follow-up.
DE Adult Blood Transfusion Female Follow-Up Studies Human HIV
Seropositivity/*EPIDEMIOLOGY/IMMUNOLOGY/*PHYSIOPATHOLOGY Male
Prevalence Risk Factors Sex Behavior Spain/EPIDEMIOLOGY Substance
Abuse, Intravenous Time Factors T4 Lymphocytes/IMMUNOLOGY MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).